Is compounded semaglutide safe? Six checks to run on a compounded GLP-1 provider before you pay
Compounded semaglutide and tirzepatide are not FDA-approved, and the FDA does not review them for safety, effectiveness or quality. You lower your risk when the provider names its pharmacy, uses a US-licensed prescriber and can show a Certificate of Analysis.
How do you tell a legitimate compounded provider from a risky one?
Run these six checks before you pay. Each one is verifiable from the provider, the pharmacy or a public register.
Before you pay, check:
- The provider names the pharmacy that fills your prescription and says whether it is a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility.
- The pharmacy shows third-party credentials: LegitScript certification, which checks that a merchant follows applicable law and is what lets a telehealth pharmacy advertise on Google and Meta, and PCAB accreditation from ACHC, which audits against USP <795> (non-sterile) and <797> (sterile injectables).
- You can get a Certificate of Analysis showing semaglutide or tirzepatide base, not a salt form.
- A US-licensed prescriber reviews your history, not a checkbox form.
- The price is all-in and transparent, with no bait introductory rate.
- Your medicine comes with clear labels, dosing instructions and a way to report side effects.
Risk signals: no pharmacy named, no prescriber consult, salt-form ingredients, prices that look too good to be true, and dosing 'protocols' that exceed FDA-approved labeling.
The FDA warns that compounded drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness, or quality.
What the FDA says about compounded GLP-1s
What's the difference between a 503A and a 503B compounding pharmacy?
A 503A pharmacy is a traditional, state-licensed pharmacy that compounds a medication for an individual patient based on a specific prescription.
A 503B outsourcing facility registers with the FDA, is inspected by the FDA on a risk-based schedule, and follows current Good Manufacturing Practice (CGMP) standards, so it can compound larger batches.
Neither produces an FDA-approved drug, but a 503B operates under more federal oversight.
When a provider names its pharmacy, you can look up the facility: 503B outsourcing facilities appear on the FDA's public registered-facilities list.
Whether a provider uses 503A or 503B, the legitimacy questions are the same: is the pharmacy named, is it accredited, and can you see a Certificate of Analysis on the API?
Is compounded semaglutide or tirzepatide even legal in 2026?
It's narrowly legal and shrinking.
The FDA removed semaglutide and tirzepatide from the drug shortage list in early 2025, which ended the broad enforcement window that had allowed mass compounding.
As of 2026, 503A pharmacies may still compound on a patient-specific basis only in limited situations, such as a documented allergy to an inactive ingredient in the brand product or a need for a dose strength that isn't commercially available; the FDA has been explicit that lower cost or greater convenience do not, by themselves, establish a 'clinical need.'
For 503B outsourcing facilities, in April 2026 the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List after finding no clinical need to compound them from bulk substances; the public comment period on that proposal closed July 30, 2026 (Docket FDA-2018-N-3240), after an extension from June 29 via FR 2026-12937.
Bottom line: a 'compounded GLP-1' offered purely because it's cheaper, with no patient-specific justification, sits in a legally exposed gray zone.
Always confirm a provider's pharmacy and prescriber are operating within these rules.
Why does the salt-form issue matter, and what is a Certificate of Analysis?
The FDA has flagged that some compounders use semaglutide sodium or semaglutide acetate, which the agency considers different active ingredients from the semaglutide base used in approved drugs (Ozempic, Wegovy).
The FDA has stated there is no evidence these salt forms are safe or effective for this use and no legal basis for using them in compounding.
A Certificate of Analysis (CoA) is a lab document from the pharmacy or its API supplier confirming the identity, purity, and potency of the active ingredient in your specific product.
A legitimate provider can supply one on request and it should show semaglutide base (or tirzepatide), not a salt form. If a provider can't or won't produce a CoA, treat that as a stop sign.
What are the real safety risks the FDA has documented with compounded GLP-1s?
Two stand out.
First, dosing errors: the FDA has reported cases where patients accidentally administered five to twenty times the intended dose after drawing medication from multi-dose vials, often because of confusion between 'units,' milliliters, and milligrams, with some cases requiring hospitalization.
Brand pens are pre-measured; compounded vials usually are not, so the burden is on you to measure correctly.
Second, the FDA has received adverse-event reports tied to compounded products, including reports involving doses beyond FDA-approved labeling.
A legitimate provider mitigates the dosing risk with clear instructions, properly labeled syringes, and prescriber guidance.
None of this makes brand-name GLP-1s automatically right for you either, but it explains why we weight clinical oversight and pharmacy transparency heavily in our scoring rather than ranking purely by price.
See our full safety center and the per-provider reviews for how each one handles this.
How should I choose between a compounded provider and a brand-name GLP-1?
Start with eligibility and oversight, then price.
Brand-name Wegovy and Zepbound are FDA-approved, pre-dosed, and increasingly available through manufacturer cash programs (for example, LillyDirect Zepbound) and, for some Medicare Part D members, the Part D coverage pathway.
Compounded versions can cost meaningfully less but are not FDA-approved, are legal only in narrow patient-specific circumstances in 2026, and put more responsibility on the provider and pharmacy to get safety right.
If you go compounded, only use a provider that names an accredited pharmacy, uses a US-licensed prescriber, and can produce a Certificate of Analysis.
Compare providers in our reviews, where each one lists its pharmacy and prescriber details, or use the homepage finder to compare medication and format options.
This is general information, not medical advice; talk to a licensed clinician about what's right for you.
Sources
- FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (not FDA-approved; salt forms; not reviewed for safety/effectiveness/quality)
- FDA, Alert: Dosing Errors Associated with Compounded Injectable Semaglutide Products (5-20x intended dose; units/mL/mg confusion; multi-dose vials)
- FDA, FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (April 2026; no clinical need; cost/convenience not 'clinical need')
- Federal Register, List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (comment period closed July 30, 2026, extended from June 29 via FR 2026-12937, Docket FDA-2018-N-3240)
- FDA, Compounding and the FDA: Questions and Answers (503A vs 503B definitions; 503B registration, inspection, CGMP)
- ACHC / PCAB, PCAB Accreditation for Compounding Pharmacies (USP <795> non-sterile, USP <797> sterile standards)
- LegitScript, Healthcare Certification (merchant/telehealth/pharmacy compliance verification)
We re-read the FDA's 503B proposal on October 17, 2026; it shows no final determination yet. This is general information, not medical advice.
Where to go next
- Screen a provider with the Safety Checker
- FDA warning letters and recalls by provider
- Compounded tirzepatide: the law and the risks
- The cheapest GLP-1 programs, ranked by monthly price
Updated October 17, 2026